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Despite the availability of effective antihypertensive drugs, there is a large
variation in response to these drugs. This study investigates whether
polymorphisms in the angiotensin converting enzyme (I/D), angiotensino-
gen (M235T), a-adducin (G460W), angiotensin II type 1 receptor (1166A/C),
or G protein b3-subunit (825C/T) gene modify the mean difference in blood
pressure levels among diuretics, b-blockers, or ACE-inhibitors users. Data
were used from the Doetinchem Cohort Study, and blood pressure data were
collected from GPs (1987–1997). A marginal generalized linear model (GEE)
was used to assess the gene–drug interaction on the mean difference in
systolic/diastolic blood pressure. In total, 625 hypertensive individuals were
included with a total of 5262 measurements of blood pressure. Only the
interaction between diuretic use and the GNB3 825C/T polymorphism was
significant (C allele versus TT systolic blood pressure (SBP): 4.33 mmHg [95%
CI: 0.14–8.54]). Thus, the mean SBP level among diuretic users may be
modified by the GNB3 825C/T polymorphism.
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Introduction
Hypertension is an important public health problem. Evidence from randomized
trials has shown that drug treatment reduces the risk of cardiovascular morbidity
and mortality.1,2 Despite the availability of a variety of effective drugs,
inadequate control of blood pressure is still common in hypertensive patients.3
Among the possible causes are, besides environmental, certain genetic char-
acteristics that could have modified the response to antihypertensive drugs.
Blood pressure levels are homeostatically maintained through complex
interactions between environmental and genetic factors. Antihypertensive drugs
lower blood pressure by acting on specific targets within this system. Obvious
candidate genes for antihypertensive drug–gene interactions are those that code
for components of a system, which is pharmacologically influenced by an
antihypertensive drug. Other candidates are genes that code for components of
the counter-regulatory system.
Examples of candidate genes for blood pressure lowering drugs are those in the
renin–angiotensin system, for example: angiotensinogen (AGT), angiotensin
converting enzyme (ACE), and angiotensin II receptor type 1 (AGTR1). Plasma
AGT is significantly elevated in patients with the AGT T235 allele,4 and serum
ACE is significantly higher in subjects with the ACE D allele.5 Candidate genes
related to other blood pressure regulating systems are a-adducin (ADD1) and
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b3-subunit of G-protein (GNB3). ADD1 may affect blood
pressure by modulating renal tubular reabsorption of
sodium through the activation of Naþ , Kþ -ATPase (adeno-
sine triphosphatase) with the 460W allele exhibiting higher
affinity for the Naþ , Kþ -ATPase pump.6 The 825T allele of
GNB3 gene is associated with a shortened splice variant of
the GNB3 protein that gives rise to enhanced signal
transduction via pertussis toxin-sensitive G-proteins.7
Several nonrandomized trials have studied the influence
of these genes on the response to antihypertensive medica-
tion,8 but with conflicting results and as far as we known,
the effect of these genes in daily practice has never been
evaluated. Therefore, the purpose of the present study was
to evaluate the relationship between the I/D (ACE), M235T
(AGT), G460W (ADD1), 1166A/C (AGTR1), and 825C/T
(GNB3) polymorphisms on the mean difference in blood
pressure levels among subjects using diuretics, b-blockers, or
ACE inhibitors in daily practice.
Results
Between 1987 and 1997, 5262 blood pressure measurements
of 625 individuals were included. During follow-up, 106
subjects used diuretics (743 measurements), 229 used b-
blockers (1480 measurements) and 77 used ACE-inhibitors
(495 measurements). In 99.4% of the hypertensive indivi-
duals, genotypes were assessed for the ACE gene, 99.9% for
the ADD1 gene, 99.9% for the AGTR1 gene, 99.3% for the
GNB3 gene, and 99.9% for the AGT gene. Characteristics for
the 625 subjects stratified by treatment or no treatment
during the first examination are presented in Table 1.
Subjects in the treated group are older and the percentage
of diabetics, female subjects, subjects receiving a low-salt
diet, or a cholesterol diet is higher compared to the
nontreated group.
Owing to the small sample size, two genotype groups were
combined in the analysis for some genes, namely the TT
(6.0% of the individuals) and GT genotype of ADD1 gene,
the CC (10.2% of the individuals) and AC genotype of
AGTR1 gene, the CC (4.6% of the individuals) and CT
genotype of GNB3 gene, and the TT (1.0% of the
individuals) and GT genotype of AGT gene. The unadjusted
difference in systolic blood pressure (SBP) and diastolic
blood pressure (DBP) for diuretics users was 3.15 mmHg
(95% CI: 4.70 to 1.60) and 3.92 mmHg (95% CI: 4.75
to 3.10), for b-blockers users 2.53 mmHg (95% CI: 3.78
to 1.27) and 2.13 mmHg (95% CI: 2.80 to 1.46), for
ACE inhibitors users 0.35 mmHg (95% CI: 1.62 to 2.32)
and 0.48 mmHg (95% CI: 0.55 to 1.52).
The mean difference in defined daily doses (DDDs)
between genotypes for users of diuretics, b-blockers, and
ACE inhibitors adjusted for potential confounders is pre-
sented in Table 2. There was no statistically significant
difference in DDDs between the different genotypes.
After adjustment for potential confounders, the mean
difference in SBP and DBP for users of diuretics, b-blockers,
and ACE inhibitors was compared between the genotype
groups (Figure 1a–c). The only statistically significant drug–
gene interaction was between diuretic users and GNB3 on
SBP level (4.33 mmHg [95% CI: 0.14–8.54]). This interaction
was not found for the mean difference in DBP (0.51 mmHg
[95% CI: 1.13 to 2.15]). In addition, we also adjusted for
persons who used another antihypertensive drug prior to
the use of a diuretic (n¼243 switchers). The reduction for
SBP after this adjustment was 4.74 mmHg (95% CI: 0.69–
8.78) and for DBP 0.51 mmHg (95% CI: 1.69 to 2.70).
Gene–gene–drug interactions
To assess gene–gene–drug interactions, the mean difference
in blood pressure was compared between combinations of
two of the five genes. Owing to the small sample size, the
genotype of the ID and II of the ACE gene were combined
and it was impossible to combine more then two genes
together.
In total, 36 gene–gene–drug interactions were possible for
SBP and DBP. Of these interactions, four were associated
with a significant difference in blood pressure (Figure 2).
Table 1 Baseline characteristics of all subjects at the first
examination stratified by treatment
Variable Untreated
(N¼490)
Treated
(N¼135)
Gender (M) 279 (56.9%) 57 (42.2%)*
Age (years) 47.779.1 52.177.6*
SBP (mmHg) 151.4718.3 144.2720.4*
DBP (mmHg) 96.2710.0 90.5710.1*
BMI (kg/m2) 28.074.5 27.573.9
Totaal/HDL cholesterol ratio 5.571.9 5.872.2
Diabetes 15 (3.1%) 14 (10.4%)*
Myocardial infarction 7 (1.4%) 1 (0.7%)
Diet for high BP 56 (11.5%) 33 (24.4%)*
Diet for high cholesterol 35 (7.1%) 24 (17.8%)*
Ethnicity, caucasian 477 (97.3%) 131 (97.8%)
Smoking
Current 167 (34.1%) 48 (35.6%)
Past 151 (30.8%) 33 (24.4%)
Never 172 (35.1%) 54 (40.0%)
ACE: DD/ID/II 160/212/114 36/72/27
ADD1: W-allele/GGa 312/92 92/43
AGTR1: C-allele/AAb 237/66 66/69
GNB3: C-allele/TTc 220/63 63/71
AGT: T-allele/MMd 164/325 51/84
Diuretic 39 (33.9%)
b-Blocker 86 (63.7%)
ACE inhibitor 10 (7.4%)
*P-valueo0.001.
aW allele: WW+GW genotype.
bC allele: CC+CA genotype.
cC allele: CC+CT genotype.
dT allele: TT+MT genotype.
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These were the interaction between diuretic use and ADD1
W alleleþAGT T allele versus GGþMM on DBP (3.09 mmHg
[95% CI: 0.16–2.93] 169 versus 149 measurements),
b-blocker use and ATR1 C alleleþAGT T allele versus
AAþMM on DBP (2.63 mmHg [95% CI: 0.30–2.33] 436
versus 223 measurements), ACE inhibitor use and ACE I
alleleþGNB TT versus DDþC allele on DBP (6.22 mmHg
[95% CI: 0.93–5.29] 180 versus 18 measurements), and ACE
inhibitor use and ACE I alleleþAGT T allele versus
DDþMM on SBP (10.21 mmHg [95% CI: 19.47 to
0.95] 239 versus 29 measurements).
Discussion
The data presented here provide evidence that subjects with
the GNB3 TT polymorphism had lower SBP levels, while on
treatment with a diuretic. None of the other examined genes
had a significant influence on blood pressure. Of the 36
possible gene–gene–drug interactions on blood pressure,
four results were significant, namely diuretic use and ADD1
W alleleþAGT T allele versus GGþMM (DBP), b-blocker use
and AGTR1 C alleleþAGT T allele versus AAþMM (DBP),
ACE inhibitor use and ACE I alleleþGNB TT versus DDþ
C-allele (DBP), and ACE inhibitor use and ACE I alleleþAGT
T allele versus DDþMM (SBP).
Our results concur with that of a nonrandomized trial that
investigated the role of GNB3 in diuretic users.9 In this
study, a significantly greater decline for both SBP and DBP
was found in subjects with the TT allele.9 To confirm these
data, additional studies (trials and observational studies) are
warranted to confirm this potential drug–gene interaction.
Especially, because no interactive effect was found in this
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Figure 1 (a) Adjusted mean difference in systolic or diastolic blood
pressure among diuretic users. The diamonds with bars depict the mean
difference in blood pressure795% CI. (b) Adjusted mean difference in
systolic or diastolic blood pressure among b-blocker users. The
diamonds with bars depict the mean difference in blood pressure795%
CI. (c) Adjusted mean difference in systolic or diastolic blood pressure
among ACE inhibitor users. The diamonds with bars depict the mean
difference in blood pressure795% CI.
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Figure 2 Adjusted interactions between the five candidate genes
resulting in a significant difference in systolic and/or diastolic blood
pressure among antihypertensive drug users. The diamonds with bars
depict the mean difference in blood pressure795% CI.
Table 2 Adjusted DDDs for antihypertensive drug users
Diuretic b-Blocker ACE inhibitor
ACE: ID versus DD 0.04 (0.32–0.24) 0.06 (0.04–0.15) 0.00 (0.38–0.37)
ACE: II versus DD 0.09 (0.26–0.44) 0.08 (0.02–0.19) 0.01 (0.42–0.44)
ADD1: W allele versus GG 0.10 (0.33–0.13) 0.00 (0.08–0.09) 0.05 (0.23–0.33)
ATR1: C allele versus AA 0.12 (0.13–0.37) 0.01 (0.07–0.08) 0.05 (0.24–0.37)
GNB3: C allele versus TT 0.01 (0.21–0.24) 0.08 (0.15–0.00) 0.17 (0.12–0.44)
AGT: T allele versus MM 0.08 (0.34–0.18) 0.01 (0.08–0.07) 0.20 (0.13–0.53)
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study on DBP and the effect found on DBP was smaller than
for example with AGT. In addition, none of the gene–gene–
drug interactions was significant with GNB3 in diuretic
users.
There are some explanations why our results might be
false-positive. First, we have tested multiple genes on
multiple outcomes and if we had adjusted for multiple
testing, the interaction between GNB3 and diuretic use
would not have been significant. A popular correction
method for multiple testing is the Bonferroni correction
(1(1–0.05) the number of markers); however, this correc-
tion would overcorrect the false-positive rate and thereby
might disregard valid information. Second, the medication
taken during the blood pressure measurement may not have
been the first antihypertensive drug, but one that through a
process of trail and error was found to be the most effective.
With an over-representation of ‘good responders’, the
chance to find a drug–gene interaction is higher. However,
after adjustment for switchers, the result remained signifi-
cant and therefore channeling of diuretics does not seem to
be the explanation. Third, observational studies compared
to trials may be vulnerable for confounding. Confounding is
also unlikely since we adjusted for potential confounders,
like dose, duration of therapy, age, gender, and comorbid-
ities. Race could be an additional confounder, but less than
1% of the subjects had a different ethnic background. In
addition, confounding by indication might have occurred in
our study. As a physician was free to choose whether a
patient receives an antihypertensive drug, and which
specific patients’ characteristics might have influenced this
decision. However, the drug–gene interaction between
subjects using the same antihypertensive class is most likely
not influenced by this bias, since users of the same
antihypertensive drug class have most likely the same
characteristics and the physician is unaware of a subjects’
genotype. There are other variables, for example, exercise
and alcohol, which have an impact on blood pressure.
Therefore, it is possible that we overestimated or under-
estimated the blood pressure lowering effect of the anti-
hypertensive drug classes. However, since this is most likely
the same for the different genotype groups, it would not
have influenced our drug–gene interaction results. Fourth,
an advantage of a trial is the possibility to assess the
response to an antihypertensive drug, by measuring the
blood pressure before treatment and during treatment.
Owing to the small number of persons with a baseline
measurement just preceding the start of an antihypertensive
drug therapy, the mean difference in blood pressure was
calculated. If the result is not false-positive, the observed
difference of 4.33 mmHg systolic could result in a relative
risk reduction of about 10% of cardiovascular disease in 10
years, according to the Framingham Risk function.
Regarding the significant gene–gene–drug interactions,
the chance of false-positives is even higher due to the
smaller sample size. However, of the 36 possible combina-
tions (SBP, DBP), four were found to be significant. The
observed interactions were only found with either SBP or
DBP. Thus, further investigations are needed before defini-
tive conclusions can be made. It is, however, apparent that
the effects of the investigated single nucleotide polymorph-
isms are probably small and that this is the same for the
gene–gene–drug interactions.
Notwithstanding these caveats, the study suggests that
some gene–gene–drug interactions were found on blood
pressure levels in daily practice. In addition, the GNB3
polymorphism of the GNB3 gene may influence the mean
difference in SBP among users of low-ceiling diuretics.
Materials and methods
Setting
Data from the Doetinchem Cohort Study were used; a
population-based prospective study on cardiovascular dis-
ease risk factor conducted in the Netherlands.10 The baseline
examination was carried out from 1987 to 1992 in men and
women aged 20–59 years, living in Doetinchem, a Dutch
town with circa 40 000 inhabitants.
Data collection
At the start of the Doetinchem Cohort Study, the respon-
dents completed a questionnaire that contained questions
on demographic variables, cardiovascular diseases, and risk
factors. In addition, weight and height were measured and
blood was drawn for total and high-density lipoprotein
(HDL) cholesterol determination and DNA extraction. The
design of this study has been described elsewhere.10 In
addition, blood pressure data was collected from general
practitioners from 1987 to 1997.
Pharmacy records were available for approximately 76% of
the Doetinchem cohort as of 1 January 1987. These records
include the name of the drug, the day of dispensing, the
dosage form, the number of units dispensed, the prescribed
daily dose, and the Anatomical Therapeutic Chemical code
of the drug.11
Cohort and outcome definition
Hypertensive patients were only included if the genotypes
could be assessed, additional blood pressure measurements
from the GPs were available, and pharmacy data were
available. In addition, during follow-up, individuals had to
haveX1 blood pressure measurement which met one of the
following criteria: SBP X160 mmHg, and/or diastolic blood
pressure (DBP) X95 mmHg, and/or the use of 1 antihyper-
tensive drug class at the time of a blood pressure measure-
ment (monotherapy). Only subjects using low-ceiling
diuretics, b-blockers, and ACE inhibitors were included in
the analysis, because of the small numbers for the other
antihypertensive drug classes. Measurements were excluded
when a combination of antihypertensive drugs was used.
The end of the study period was set at 31 December 1997.
Potential confounders and effect modifiers
As potential confounders, we considered age, sex, body mass
index, defined daily dose, smoking at baseline, history of
myocardial infarction, diabetes mellitus at baseline, use of
nitrates, use of statins, use of NSAIDs, total/hdl cholesterol
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level, low-salt diet, low-cholesterol diet, the use of another
antihypertensive drug class 2 weeks prior to the blood
pressure measurement, the use of an antihypertensive drug
6 of the 8 weeks prior to the blood pressure measurement,
and the date of the measurement. To compare dosages of
different antihypertensive drugs in our analysis, we used the
prescribed daily dose (PDD), expressed as the number of
DDDs per day. The DDD is defined as the recommended
dose for the main indication in an adult of 70 kg.12
Genotype
Genomic DNA was isolated from peripheral blood according
to standard procedures. The genotyping procedure of ADD1
G460W,13 ACE I/D,5 AGT M235T,14 GNB3 825C/T,15 and
AGTR1 1166A/C16 was previously described.
Analysis
We used ANOVA (continuous variables) and w2 testing
(categorical variables) to compare baseline characteristics
of people with different genotypes. A marginal generalized
linear model (GEE) was used to study the potential
interaction between the genetic polymorphisms of interest
and response to antihypertensive treatment for two out-
comes: mean difference in SBP and DBP. We compared the
mean SBP and DBP levels between the different genotype
groups for subjects using the same antihypertensive drug
class. To test for the interaction between the polymorphism
in question (e.g. ACE I/D polymorphism) and the use of an
antihypertensive drug class in question (e.g. ACE-inhibi-
tors), two dummy variables were added to the model: ACE
genotype (ID and II) the use of ACE inhibitors during the
blood pressure measurement (0/1). The reference group
consisted of subjects with the DD genotype, who had a
prescription of the antihypertensive drug class in question.
The mean blood pressure of treated subjects was defined as
the mean blood pressure of subjects who used the anti-
hypertensive drug class in question minus the mean blood
pressure in untreated subjects with the same genotype. For
the gene–gene–drug interaction, we combined the geno-
types of two of the five polymorphisms. For this analysis, we
added three dummy variables to the model, that is, the
drug–gene combinations (e.g. ACEþADD1: I alleleþT
allele, I alleleþMM, and D alleleþT allele) the use of the
antihypertensive drug class in question (0/1). The GEE was
used to account for intraperson correlations among repeated
measurements. To compare the difference in DDD, the
model was used stratified for the different genotypes. The
covariance matrix of the repeated dependent measurements
was exchangeable and data were analysed using SAS
statistical software and adjusted for potential confounders.
Acknowledgments
This study was financially supported by The Netherlands Heart
Foundation, grant number: 2001.064; the Ministry of Health,
Welfare and Sport of the Netherlands, and the National Institute
for Public Health and the Environment, Bilthoven, The Nether-
lands.
References
1 Collins R, MacMahon S. Blood pressure, antihypertensive drug treat-
ment and the risks of stroke and of coronary heart disease. Br Med Bull
1994; 50: 272–298.
2 Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B et al.
Randomised trial of old and new antihypertensive drugs in elderly
patients: cardiovascular mortality and morbidity in the Swedish Trial in
Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751–1756.
3 Schelleman H, Klungel OH, Kromhout D, de Boer A, Stricker BHCh,
Verschuren WMM. Prevalence and determinats of undertreatment of
hypertension in the Netherlands. J Hum Hypert 2004; 18: 317–324.
4 Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS,
Charru A et al. Molecular basis of human hypertension: role of
angiotensinogen. Cell 1992; 71: 169–180.
5 Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An
insertion/deletion polymorphism in the angiotensin I-converting en-
zyme gene accounting for half the variance of serum enzyme levels. J
Clin Invest 1990; 86: 1343–1346.
6 Manunta P, Cusi D, Barlassina C, Righetti M, Lanzani C, D’Amico M et
al. Alpha-adducin polymorphisms and renal sodium handling in
essential hypertensive patients. Kidney Int 1998; 53: 1471–1478.
7 Virchow S, Ansorge N, Rubben H, Siffert G, Siffert W. Enhanced fMLP-
stimulated chemotaxis in human neutrophils from individuals carrying
the G protein beta3 subunit 825 T-allele. FEBS Lett 1998; 436: 155–158.
8 Schelleman H, Stricker BH, De Boer A, Kroon AA, Verschuren MW, Van
Duijn CM et al. Drug–gene interactions between genetic polymorph-
isms and antihypertensive therapy. Drugs 2004; 64: 1801–1816.
9 Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T poly-
morphism of the G protein beta(3)-subunit and antihypertensive
response to a thiazide diuretic. Hypertension 2001; 37: 739–743.
10 Verschuren WMM, Leer van EM, Blokstra A, Seidell JC, Smit HA, Bueno
de Mesquita HB et al. Cardiovascular disease risk factors in The
Netherlands. Neth J Cardiol 1993; 4: 205–210.
11 World Health Organization. International Classification of Diseases, 10th
Revision (ICD-10). WHO Switzerland, World Health Organization:
Geneva, 1992.
12 Anonymous. Guidelines for ATC Classification and DDD Assignment, 3rd
edn. WHO collaberating Centre for drug statistics Methodology: Oslo,
2000.
13 Beeks E, Janssen RG, Kroon AA, Keulen ET, Geurts JM, de Leeuw PW et
al. Association between the alpha-adducin Gly460Trp polymorphism
and systolic blood pressure in familial combined hyperlipidemia. Am J
Hypertens 2001; 14: 1185–1190.
14 Russ AP, Maerz W, Ruzicka V, Stein U, Gross W. Rapid detection of the
hypertension-associated Met235–4Thr allele of the human angiotensi-
nogen gene. Hum Mol Genet 1993; 2: 609–610.
15 Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R et al.
Association of a human G-protein beta3 subunit variant with hyperten-
sion. Nat Genet 1998; 18: 45–48.
16 Henskens LH, Spiering W, Stoffers HE, Soomers FL, Vlietinck RF, de
Leeuw PW et al. Effects of ACE I/D and AT1R-A1166C polymorphisms
on blood pressure in a healthy normotensive primary care population:
first results of the Hippocates study. J Hypertens 2003; 21: 81–86.
Five candidate genes and antihypertensive drugs
H Schelleman et al
26
The Pharmacogenomics Journal
